Becton Dickinson & Co
BDX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$771.00 | Tjghqq | Jlbwcbbn |
Becton, Dickinson's 2022 Success Depends on Alaris
Business Strategy and Outlook
While 2020 was a challenging year for Becton, Dickinson, or BD, 2021 has been better, buoyed by Veritor demand in particular. Much uncertainty resides in the return of BD's pump infusion system (Alaris) to the market, which could be a material catalyst for the company that will see some challenging comps as testing revenue wanes.